<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03422887</url>
  </required_header>
  <id_info>
    <org_study_id>201802</org_study_id>
    <nct_id>NCT03422887</nct_id>
  </id_info>
  <brief_title>Nalbuphine and Flurbiprofen for Oculoplastic Surgery</brief_title>
  <official_title>Flurbiprofen Axetil and Nalbuphine for Postoperative Pain and Discomfort After Oculoplastic Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the postoperative pain and discomfort using
      flurbiprofen axetil or nalbuphine administration after oculoplastic surgery under general
      anesthesia.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In this randomized controlled clinical trial, we evaluated the postoperative analgesic
      efficacy and adverse effects of flurbiprofen axetil combined with nalbuphine in patients
      undergoing oculoplastic surgery compared with a single dose of flurbiprofen axetil or
      nalbuphine.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 18, 2018</start_date>
  <completion_date type="Anticipated">September 30, 2018</completion_date>
  <primary_completion_date type="Actual">August 31, 2018</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain 24 hours after recovery</measure>
    <time_frame>24 hours after recovery</time_frame>
    <description>Pain levels measured using Numerical Rating Scale (NRS) ranging from 0 to 10, where 0 represents no pain and 10 represents the worst pain imaginable ; this scale has been confirmed to be sensitive and reliable.Clinically significant postoperative pain was considered serious pain (NRS score ≥5).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Discomfort 24 hours after recovery</measure>
    <time_frame>24 hour after recovery</time_frame>
    <description>Discomfort levels were measured using Numerical Rating Scale (NRS) ranging from 0 to 10, where 0 represents no discomfort and 10 represents the worst discomfort; this scale has been confirmed to be sensitive and reliable. Discomfort was defined as &quot;sensation other than pain&quot; and included nausea, vomiting, headache, and dizziness. Clinically significant postoperative discomfort was considered serious discomfort (NRS score ≥5) any time postoperatively.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">330</enrollment>
  <condition>Surgery</condition>
  <condition>Anesthesia</condition>
  <condition>Pain</condition>
  <arm_group>
    <arm_group_label>flurbiprofen axetil</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>flurbiprofen axetil intraoperative administration 100mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nalbuphine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>nalbuphine intraoperative administration 0.1mg/kg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nalbuphine and flurbiprofen axetil</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>flurbiprofen axetil intraoperative administration 100mg and nalbuphine intraoperative administration 0.1mg/kg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nalbuphine</intervention_name>
    <description>Nalbuphine administration during surgery</description>
    <arm_group_label>nalbuphine</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flurbiprofen Axetil</intervention_name>
    <description>Flurbiprofen axetil administration during surgery</description>
    <arm_group_label>flurbiprofen axetil</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nalbuphine and Flurbiprofen Axetil</intervention_name>
    <description>Nalbuphine and Flurbiprofen Axetil administration during surgery</description>
    <arm_group_label>nalbuphine and flurbiprofen axetil</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Undergoing oculoplastic surgery

          -  age between 16 and 75 years

          -  American Society of Anesthesiologists (ASA) physical status of I-II

        Exclusion Criteria:

          -  serious coexisting disease

          -  body mass index (BMI) &lt;18.5 or &gt;35

          -  contraindications or previous adverse reactions to any of the drugs used

          -  females with a positive pregnancy test

          -  patients unable to cooperate
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Huijing Ye</last_name>
    <role>Study Director</role>
    <affiliation>Sun Yat-sen University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Huijing Ye</last_name>
    <phone>+00862087331539</phone>
    <email>yehuijing@qq.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Huasheng Yang</last_name>
    <phone>+00862087331539</phone>
    <email>yanghs64@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Sun Yat-sen University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Huijing Ye, Master</last_name>
      <phone>00862087331539</phone>
      <email>yehuijing@qq.com</email>
    </contact>
    <contact_backup>
      <last_name>Huasheng Yang, Doctor</last_name>
      <phone>00862087331539</phone>
      <email>yanghs64@126.com</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>January 18, 2018</study_first_submitted>
  <study_first_submitted_qc>January 30, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 6, 2018</study_first_posted>
  <last_update_submitted>September 4, 2018</last_update_submitted>
  <last_update_submitted_qc>September 4, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Huijing Ye</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>postoperative pain</keyword>
  <keyword>general anesthesia</keyword>
  <keyword>postoperative discomfort</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Flurbiprofen</mesh_term>
    <mesh_term>Flurbiprofen axetil</mesh_term>
    <mesh_term>Nalbuphine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

